CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.84B, above the global median of $1.15B
- FinancialsAltman Z-Score 1.1: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.84BUSDvs all stocks (USD)
Revenue (TTM)
674.41MUSDvs all stocks (USD)
Profit Margin
-25.66%vs Medical Devices peers
Beta
0.9350xvs all stocks
52-Week Change
-1.12%vs all stocks
Market Capitalization
1.84BUSDvs all stocks (USD)
Enterprise Value
1.65BUSDvs all stocks (USD)
Forward P/E
-15.03xvs Medical Devices peers
Price to Sales (TTM)
2.73xvs Medical Devices peers
Price to Book (MRQ)
5.58xvs Medical Devices peers
Enterprise to Revenue
2.44xvs Medical Devices peers
Enterprise to EBITDA
-9.91xvs Medical Devices peers
Gross Margin
77.63%vs Medical Devices peers
Profit Margin
-25.66%vs Medical Devices peers
Operating Margin
-38.73%vs Medical Devices peers
Return on Assets (TTM)
-11.06%vs Medical Devices peers
Return on Equity (TTM)
-49.96%vs Medical Devices peers
Revenue (TTM)
674.41MUSDvs all stocks (USD)
Revenue per Share (TTM)
6.00USDUpdated Jul 19, 2026Quarterly Revenue Growth
12.30%vs Medical Devices peers
Gross Profit (TTM)
508.84MUSDvs all stocks (USD)
EBITDA (TTM)
-166.22MUSDvs all stocks (USD)
Net Income (TTM)
-173.05MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
12.30%vs Medical Devices peers
Operating Cash Flow (TTM)
-26.88MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
5.08MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
655.35MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
166.88MUSDFY2025 · Dec 31, 2025Gross Profit
488.47MUSDFY2025 · Dec 31, 2025Operating Income
-153.80MUSDvs all stocks (USD)
Pre-tax Income
-136.25MUSDFY2025 · Dec 31, 2025Income Tax Expense
-23.00KUSDFY2025 · Dec 31, 2025Net Income
-136.23MUSDFY2025 · Dec 31, 2025EBIT
-119.21MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-100.24MUSDFY2025 · Dec 31, 2025Research & Development
224.54MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
417.73MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.87MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
17.04MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.22USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.22USDFY2025 · Dec 31, 2025Basic Shares Outstanding
111.47MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
111.47MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-136.23MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-50.83MUSDFY2025 · Dec 31, 2025Free Cash Flow
-77.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
103.39MUSDFY2025 · Dec 31, 2025Income Tax Paid
30.67MUSDFY2025 · Dec 31, 2025Interest Paid
13.41MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-136.23MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
14.65MUSDFY2025 · Dec 31, 2025Stock-based Compensation
104.83MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.95MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-38.94MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-95.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-26.65MUSDFY2025 · Dec 31, 2025Purchase of Investments
-821.08MUSDFY2025 · Dec 31, 2025Sale of Investments
1.28BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
437.28MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
99.98MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-560.95MUSDFY2025 · Dec 31, 2025Other Financing Charges
-146.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-457.46MUSDFY2025 · Dec 31, 2025Shares Outstanding
115.82MSharesUpdated Jul 19, 2026Float Shares
95.22MSharesUpdated Jul 19, 2026Shares Short
11.88MSharesUpdated Jul 19, 2026Short Ratio
6.65daysvs all stocks
Short % of Shares Outstanding
13.90%vs all stocks
% Held by Insiders
10.01%vs all stocks
% Held by Institutions
87.45%vs all stocks
Total Cash (MRQ)
432.00MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.73USDUpdated Jul 19, 2026Total Debt (MRQ)
234.94MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.7104xvs Medical Devices peers
Current Ratio (MRQ)
2.90xvs Medical Devices peers
Book Value per Share (MRQ)
2.85USDUpdated Jul 19, 2026Total Assets
804.33MUSDvs all stocks (USD)
Total Current Assets
646.73MUSDFY2025 · Dec 31, 2025Total Liabilities
463.86MUSDFY2025 · Dec 31, 2025Total Non-current Assets
157.59MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
240.63MUSDFY2025 · Dec 31, 2025Total Current Liabilities
223.23MUSDFY2025 · Dec 31, 2025Cash
7.40MUSDFY2025 · Dec 31, 2025Cash Equivalents
86.15MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
93.55MUSDFY2025 · Dec 31, 2025Other Short-term Investments
354.13MUSDFY2025 · Dec 31, 2025Accounts Receivable
89.44MUSDFY2025 · Dec 31, 2025Inventory
41.11MUSDFY2025 · Dec 31, 2025Accounts Payable
122.23MUSDFY2025 · Dec 31, 2025Short-term Debt
11.66MUSDFY2025 · Dec 31, 2025Deferred Revenue
15.95MUSDFY2025 · Dec 31, 2025Long-term Debt
236.69MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-1.29BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
340.47MUSDvs all stocks (USD)
52-Week Low
9.82USDUpdated Jul 19, 202652-Week High
18.92USDUpdated Jul 19, 202652-Week Change
-1.12%vs all stocks
Beta
0.9350xvs all stocks
50-Day MA
16.77USDUpdated Jul 19, 2026200-Day MA
13.67USDUpdated Jul 19, 2026Avg 10-Day Volume
1.42MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.68MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.53USDUpdated Jul 19, 2026Other Income / Expense
-4.32MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.78Profit Margin: -0.26
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.90Altman Z-Score: 1.10
Financial Health
Altman Z-Score 1.1: distress zoneCritical
Altman Z-Score: 1.10
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.84B, above the global median of $1.15BNotable
Market cap (USD): 1,843,869,364Global Median: 1,146,734,693.424
Revenue is $674.41M, above the global median of $520.53MNotable
Revenue (USD): 674,414,016Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Chipscreen Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Edge Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ascletis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Mirxes Holding Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guobang Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Ningbo Huaxiang Electronic Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Jiangxi Black Cat Carbon Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Youcare Pharmaceutical Group Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated